Sector News

UCB sells generics unit Kremers Urban for $1.53 billion

November 7, 2014
Life sciences
UCB is selling its US specialty generics business Kremers Urban Pharmaceuticals to two private equity groups for almost $1.53 billion.
 
The cash from Advent International and Avista Capital Partners will be used by Belgium-headquartered UCB “to reduce indebtedness and increase the company’s capacity strategic investments”. The deal is expected to close by the first quarter of 2015.
 
Kremers Urban focuses on difficult, ‘high-barrier-to-entry’ generics and UCB got hold of the New Jersey-based business through its acquisition of Schwarz Pharma in 2006.
 
UCB chief financial officer Detlef Thielgen said it “has been an important enabler” to build the group’s operations. However, “it’s now the right time from a value perspective to focus on our core business” of neurology and immunology.
 
The sale was announced after another Belgian firm, the over-the-counter group Omega Pharma, announced it was being acquired by Perrigo in a deal worth $4.5 billion.
 
By Kevin Grogan
 
Source: Pharma Times

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]